At the end of last year, we discovered targeted attacks against aerospace and military companies in Europe and the Middle East, active from September to December 2019. A collaborative investigation ...

The system targets equipment such as haul trucks, loaders, bulldozers, and excavators, at construction sites, mines, quarries, and industrial plants Jerusalem /PRNewswire/ - Israeli startup Ception ...

Ception's lead product is reslizumab. Reslizumab is a humanized monoclonal antibody (mAb) against interleukin-5 (IL-5) currently in a Phase IIb/III clinical trial for the treatment of pediatric ...

Malvern, Pa.-based Ception Therapeutics, a biotech developing drugs to treat inflammatory disease, raised an additional $14.7 million in its third funding round, bringing the total round to $77 ...

If Phase III data on eosinophilic esophagitis drug is positive, Cephalon will pay $250 million to take over Ception. Cephalon will pay $100 million up front for an option to purchase Ception ...

Ception is reporting mixed results from a Phase IIb/III trial of Cinquil (reslizumab), a drug for a type of inflammation of the esophagus called pediatric eosinophilic esophagitis. Patients taking the ...

MALVERN, Pa. and FRAZER, Pa., Nov. 23 /PRNewswire-FirstCall/ -- Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. (Nasdaq ...

After reporting positive Phase II clinical results for its asthma treatment reslizumab, Ception Therapeutics is being acquired by Cephalon for $250 million. Cephalon paid $100 million for an option to ...

Cephalon and Ception Therapeutics have entered into an agreement that provides Cephalon with an option to purchase all outstanding capital stock of Ception. Ception's lead drug is reslizumab, a ...